Diligence memo · auto-generated · as of July 2, 2026
Immunocore Holdings plc
Immunocore Holdings plc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Immunocore Holdings plc operates in Biotechnology, based in Abingdon, Oxfordshire.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Immunocore Holdings plc has raised $140M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $140M on 2022-07-20.
Most recent recorded round closed around 2022-07-20.
Valuation (modeled)modeled
Provath models Immunocore Holdings plc at approximately $2.9B (range $635M–$5.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.46× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era. Within the normal band (146% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 4.0 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 94% of Biotechnology peers (4293 compared).
Modeled value ranks above 97% of those peers.
Closest niche peers: Areteia Therapeutics, Inc., GIO World Health Ltd, Crinetics Pharmaceuticals, Inc., 2seventy bio, Inc., Gio World Health (Europe) Sa.
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.